TrumpRx adds more than 600 generics in deals with Mark Cuban’s Cost Plus Drugs, Amazon and GoodRx

President Donald Trump on Monday announced that more than 600 generic medications are being added to TrumpRx.gov, the federal drug-pricing comparison website, through new partnerships with Amazon Pharmacy, GoodRx and Mark Cuban Cost Plus Drugs.

The move significantly expands a site that until now had mostly featured brand-name drugs, including high-priced obesity treatments and fertility medications. Generics added Monday include widely prescribed therapies such as atorvastatin, clopidogrel, lisinopril and metformin, with many priced under $5, according to a White House fact sheet. The site will not list controlled substances, drugs with FDA-mandated risk evaluation and mitigation strategies, or medications not typically sold through direct-to-consumer channels.

Approximately 90% of prescriptions filled in the United States are generic.

“This has been the greatest breakthrough in lowering health care costs in modern history, but we’re just sort of getting started,” Trump said in a speech at the White House alongside Cuban and other industry partners, calling TrumpRx "the hottest thing in medicine.” According to the President, the site has been visited more than 10 million times since its February 2026 launch.

Related content: Trump and health care: 8 key points from the State of the Union

How TrumpRx works

TrumpRx is not a pharmacy. It directs visitors to drugmakers' direct-to-consumer pages and provides coupons that can be used at retail pharmacies. The prices listed are for cash-paying customers, and the site advises patients to check whether they would pay less through insurance.

With Monday's expansion, some product pages now include a neighborhood map that lets users compare cash prices across local pharmacies. In some cases, the site will route users to Cost Plus Drugs, the mail-order pharmacy Cuban co-founded in 2022 that now offers more than 2,300 medications and marks up generics by approximately 15% over their negotiated price.

The new generic listings will appear separately from the brand-name drugs offered through Trump's Most-Favored-Nation pricing agreements with manufacturers.

Savings depend on coverage

The cash discounts aggregated on TrumpRx will not benefit every patient equally.

The Associated Press reported a conversation with Rena Conti, Ph.D., a professor at Boston University's Questrom School of Business, who said that most insured patients will still come out ahead by using their coverage rather than paying cash through TrumpRx. Patients without insurance and those with still-unmet high deductibles are the most likely to benefit from the cash discounts now aggregated on the site.

Cuban, an independent, has been a frequent critic of Trump but praised Monday's deal as a "special partnership." In a recent post on X, he wrote: "Everyone wants me to rip on TrumpRx. Reality is, it's saving patients money on IVF [in vitro fertilization] and a few other drugs. A lot of money."

Trump, addressing Cuban at the event, said the two share at least one priority. "We have the same thing, one thing, in common: We want to make people better, and keep them wealthy," he said.

Related content: Mark Cuban’s direct-to-consumer online pharmacy makes insurance look unnecessary

The broader drug pricing push

Monday’s announcement is the latest in a series of moves the administration has rolled out under Trump's May 2025 executive order on Most-Favored-Nation (MFN) drug pricing, which directs federal agencies to push U.S. prices toward what other developed countries pay.

Since September 2025, the White House has announced 17 deals with major pharmaceutical manufacturers under the policy, exempting some from threatened tariffs in exchange for price concessions and direct-to-consumer offerings. Lawmakers from both parties have asked to review the contracts, which have not been made public.

In December 2025, the Office of the U.S. Trade Representative, the Commerce Department and the Department of Health and Human Services announced an agreement with the United Kingdom that the administration said would raise the net price of new prescription drugs there by 25%. In January, Trump called on Congress to pass what the administration has branded “The Great Healthcare Plan,” which would codify the MFN savings and tighten insurance regulations.

A relatively narrow group of patients will see immediate, direct savings from the moves. Certain Medicare beneficiaries are set to qualify for $50-a-month obesity drugs under the deals, but broader affordability pressures, including the expiration of enhanced Affordable Care Act subsidies, remain a top concern heading into the November midterm elections.